Colon Cancer

The authors were unable to adequately address these concerns, noting that, due to the time elapsed since the original publication, retrieval of the underlying raw data for verification would be difficult. The authors therefore requested the retraction of the article.

P=N/A, N=1200, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Initiation date: Jan 2026 --> Jul 2026

P3, N=1083, Recruiting, Maimónides Biomedical Research Institute of Córdoba | Not yet recruiting --> Recruiting

This case demonstrates that osimertinib can achieve an early, deep, and sustainable response in patients with a rare G719A/L861Q co-mutation. Prospective evidence is necessary for rare EGFR subtypes.

Molecular docking studies were performed on representative active compounds to rationalize observed biological activity and characterize key interactions within the ATP-binding sites of EGFR and B-RAF kinases. Collectively, these findings identify khellin-derived benzofuran-pyrazoline hybrid systems as promising candidates for targeting kinases and as potential anticancer agents, providing a rational basis for further structural optimization and mechanistic investigation.

The most potent derivative identified was 2-(3-(benzo[d]thiazol-2-yl)-1H-indol-1-yl)-N-(2,4-dimethoxyphenyl)acetamide (9d) which demonstrated IC50 values of 7.9 ± 1.6, 16.1 ± 0.5, and 9.3 ± 2.2 µM against A549, SW480, and HepG2 cells, respectively, comparable or even superior to those of cisplatin (IC50s were 5.7 ± 1.6, 15.2 ± 0.3, and 14.3 ± 1.9 µM for A549, SW480, and HepG2 cells, respectively)...In silico predictions regarding drug-likeness, pharmacokinetics, and toxicological characteristics suggest that the promising derivative 9d could be proposed as a potential anticancer drug for further preclinical studies. Molecular docking studies revealed that 9d was well accommodated within the endothelial growth factor receptor (EGFR) active site.

Collectively, PRAS40/SP1/SLC7A5 axis drives macrophage pro-inflammatory polarization by enhancing leucine and tryptophan uptake, thereby exacerbating IBD. These findings highlight the importance of amino acid reprogramming in macrophage polarization during IBD progression and propose targeting this axis as a potential therapeutic strategy for IBD.

CD8+ TIGR cells potently kill macrophages activated by intestinal damage or disease using Fas ligand (FasL) and TNF-related weak inducer of apoptosis (TWEAK). The identification of CD8+ TIGR cells yields new insights into organ-specific immune regulation and potential therapeutics for IBD.

Our findings indicate that CUL7 mediates NRF2 signaling through promoting the KEAP1 ubiquitination, a mechanism that is integral to colon cancer progression. Collectively, these results establish CUL7 as a potential therapeutic target for colon cancer.

In syngeneic tumor models, ZY-MY-111 achieved 49% tumor growth inhibition in CT26 colon carcinoma (P < 0.001) and 56% tumor growth inhibition in A20 lymphoma (P < 0.001) by remodeling the immunosuppressive microenvironment: increasing CD8+/CD4+ T cell ratios, reducing myeloid-derived suppressor cells (MDSCs, 59% decrease), and enhancing effector memory T cell infiltration. Our findings position IL4I1 inhibition as a potential strategy to restore anti-tumor immunity.

We propose personalized risk stratification integrating demographics, microbial signatures, and metabolic biomarkers. Interventions include gut-restricted FXR agonists, probiotics, and Mediterranean diet. Future directions include prospective validation and dynamic network modeling.

Metabolomic profiling using HPLC and GC-MS revealed strain-specific signatures dominated by organic acids, volatile compounds, and fatty acids associated with oxidative, inflammatory, and apoptotic modulation. Collectively, these findings demonstrate that freeze-dried CFS exert anticancer effects through coordinated transcriptomic-independent, proteomic, and metabolomic mechanisms, highlighting their potential as multifunctional postbiotic candidates for colorectal cancer intervention.